RESUMEN
. It has been reported that some autoimmune diseases are associated with dry eye syndrome. There are limited studies that relates dry eye syndrome in patients with Familial Mediterranean fever (FMF). The aim of this study is to evaluate the relationship between dry eye syndrome in patients with FMF comparing with healthy controls. Methods. Prospective cross-sectional study was carried out in departments of physical medicine and rehabilitation and ophthalmology clinics in a tertiary public institution with a sample of 46 participants including 23 FMF patients and 23 healthy controls. Detailed eye examination was performed in all cases and indicators of xerophthalmia were assessed by Schirmer-I test, tear break-up time (TBUT) and ocular surface disease index (OSDI). In patient group; results of FMF gene analysis, acute phase reactants, concomitant diseases and number of FMF attacks were noted. Results. The average Schirmer-I test results for right-eye were recorded as 14.74±8.38 for the FMF group and 13.09±10.54 for the healthy group; the TBUT scores were 14.69±5.32 in FMF group and 15±6.45 in the healthy group; and OSDI scores were 9.04±2.75 and 10.86±1.77 in the FMF group and the healthy control, respectively.There were no statistically significant differences between FMF and control groups in terms of Schirmer-I, TBUT, and OSDI scores (all p＞0.05). No correlation was identified between acute phase reactants and the OSDI, TBUT and Schirmer-I tests for right-eye (all p＞0.05). Conclusion. This study identified no correlation between dry eye and FMF. Ocular pathology is rare and infrequently reported in FMF.
RESUMEN
The effects of moclobemide on damaged ovarian tissue induced by is-chemia-reperfusion and damaged contralateral ovarian tissue were investigated in rats, biochemically and histologically. In this experimental study, 40 rats were equally divided into four groups: 10 mg/kg moclobemide, 20 mg/kg moclobemide, ischemia/reperfusion control, and intact control groups. A 2-2.5-cm-long vertical incision was made in the lower abdomen of each rat in order to reach the ovaries, after which a vascular clip was placed on the lower side of the right ovary of each animal in the two treatment groups and the ischemia-reperfusion control group, but not in the healthy [intact control] animal group. The purpose of this procedure was to create ischemia over the course of three hours, then the clips were unclamped to provide reperfusion for the next two hours. At the end of the two hours of reperfusion, all the animals were killed by high-dose anaesthesia and their ovaries were taken and subjected to histological and biochemical [malondialdehyde, nitric oxide, glutathione] studies. The obtained results showed that moclobemide suppressed nitric oxide and malondialdehyde production in the ischemia - reperfusion damage area, and prevented the decrease in endogenous antioxidant levels [glutathione] in the rat ovarian tissue. Moclobemide also prevented infiltration of leukocytes to the ovarian tissue. These results showed that moclobemide protected ovarian tissue against ischemia-reperfusion injury. This study shows that moclobemide represses malondialdehyde and nitric oxide production in the rat ovarian tissue subjected to ischemia-reperfusion injury and keeps the endogenous antioxidant glutathione level from decreasing. Moclobemide also inhibits leukocytic migration into ovarian tissue following ischemia-reperfusion injury. From these results, it is suggested that moclobemide can be used in the treatment of ovarian ischemia-reperfusion injury